3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Leukemia, Myeloid, Acute
2
Urinary Bladder Neoplasms
1
Urethral Neoplasms
1
Ureteral Neoplasms
1
Myelodysplastic Syndromes
1
Leukemia, Promyelocytic, Acute
1
Carcinoma, Transitional Cell
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Gemcitabine
6
Specimen Handling
4
Cisplatin
4
pembrolizumab
3
enfortumab vedotin
3
atezolizumab
3
Nivolumab
3
Magnetic Resonance Spectroscopy
3
Carboplatin
3
vinflunine
2
eribulin
2
avelumab
2
Standard of Care
2
Biopsy
2
vandetanib
1
tocilizumab
1
tamibarotene
1
rucaparib
1
relatlimab
1
pegfilgrastim
1
merphos
1
guadecitabine
1
genexol-PM
1
dehydroftorafur
1
carotuximab
1
Vitamin D
1
Vinblastine
1
Ramucirumab
1
Radiotherapy
1
Radiation
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Ureteral Neoplasms
×
tamibarotene
×
Clear all
NCT06983210
2025-08-14
GRAPE
Nagoya University
Phase 2
Recruiting
43 enrolled